Literature DB >> 30336420

Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.

Itzel Jatziri Contreras-García1, Luz Adriana Pichardo-Macías2, César Emmanuel Santana-Gómez3, Karla Sánchez-Huerta4, Rogelio Ramírez-Hernández4, Beatriz Gómez-González5, Luisa Rocha3, Julieta G Mendoza Torreblanca6.   

Abstract

Synaptic vesicle protein 2A (SV2A) has become an attractive target of investigation because of its role in the pathophysiology of epilepsy; SV2A is expressed ubiquitously throughout the brain in all nerve terminals independently of their neurotransmitter content and plays an important but poorly defined role in neurotransmission. Previous studies have shown that modifications in the SV2A protein expression could be a direct consequence of disease severity. Furthermore, these SV2A modifications may depend on specific changes in the nerve tissue following the induction of epilepsy and might be present in both excitatory and inhibitory terminals. Thus, we evaluated SV2A protein expression throughout the hippocampi of lithium-pilocarpine rats after status epilepticus (SE) and during early and late epilepsy. In addition, we determined the γ-aminobutyric acid (GABA)ergic or glutamatergic nature associated with SV2A modifications. Wistar rats were treated with lithium-pilocarpine to induce SE and subsequently were shown to present spontaneous recurrent seizures (SRS). Later, we conducted an exhaustive semi-quantitative analysis of SV2A optical density (OD) throughout the hippocampus by immunohistochemistry. Levels of the SV2A protein were substantially increased in layers formed by principal neurons after SE, mainly because of GABAergic activity. No changes were observed in the early stage of epilepsy. In the late stage of epilepsy, there were minor changes in SV2A OD compared with the robust modifications of SE; however, SV2A protein expression generally showed an increment reaching significant differences in two dendritic layers and hilus, without clear modifications of GABAergic or glutamatergic systems. Our results suggest that the SV2A variations may depend on several factors, such as neuronal activity, and might appear in both excitatory and inhibitory systems depending on the epilepsy stage.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lithium-pilocarpine; SV2A protein; Status epilepticus; Temporal lobe epilepsy; VGAT; VGLUT 1

Mesh:

Substances:

Year:  2018        PMID: 30336420     DOI: 10.1016/j.yebeh.2018.08.023

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  5 in total

1.  Reductions in Synaptic Vesicle Glycoprotein 2 Isoforms in the Cortex and Hippocampus in a Rat Model of Traumatic Brain Injury.

Authors:  Katherine M Fronczak; Youming Li; Jeremy Henchir; C Edward Dixon; Shaun W Carlson
Journal:  Mol Neurobiol       Date:  2021-08-25       Impact factor: 5.682

Review 2.  Levetiracetam Mechanisms of Action: From Molecules to Systems.

Authors:  Itzel Jatziri Contreras-García; Noemí Cárdenas-Rodríguez; Antonio Romo-Mancillas; Cindy Bandala; Sergio R Zamudio; Saúl Gómez-Manzo; Beatriz Hernández-Ochoa; Julieta Griselda Mendoza-Torreblanca; Luz Adriana Pichardo-Macías
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

Review 3.  Synaptic Vesicle Glycoprotein 2A: Features and Functions.

Authors:  Rachele Rossi; Shokouh Arjmand; Simone Larsen Bærentzen; Albert Gjedde; Anne M Landau
Journal:  Front Neurosci       Date:  2022-04-28       Impact factor: 5.152

4.  Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.

Authors:  Itzel Jatziri Contreras-García; Gisela Gómez-Lira; Bryan Víctor Phillips-Farfán; Luz Adriana Pichardo-Macías; Mercedes Edna García-Cruz; Juan Luis Chávez-Pacheco; Julieta G Mendoza-Torreblanca
Journal:  Brain Sci       Date:  2021-04-23

Review 5.  Imaging Synaptic Density: The Next Holy Grail of Neuroscience?

Authors:  Maria Elisa Serrano; Eugene Kim; Marija M Petrinovic; Federico Turkheimer; Diana Cash
Journal:  Front Neurosci       Date:  2022-03-25       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.